An Open-Label Biomarker Study of ATH434 in Multiple System Atrophy
Latest Information Update: 08 May 2025
At a glance
- Drugs ATH 434 (Primary)
- Indications Multiple system atrophy
- Focus Biomarker; Therapeutic Use
- Acronyms ATH434-202
- Sponsors Alterity Therapeutics
Most Recent Events
- 30 Apr 2025 According to an Alterity Therapeutics media release, data from this study are expected mid-year
- 27 Mar 2025 Status changed from active, no longer recruiting to completed according to an Alterity Therapeutics media release.
- 10 Feb 2025 According to an Alterity Therapeutics media release, company announced that it has received binding commitments for a capital raising of A$40.0 million via a two tranche placement to Australian and international institutions and other unrelated sophisticated, professional or exempt investors. Funds to be used primarily to advance development of ATH434 .